Are you ready? EU’s Clinical Trials Regulation and portal goes live 31 January
The EU’s Clinical Trials Regulation and information system aims to streamline applications and bolster transparency – but initial rollout could…
By
Homepage
Latest in
Homepage
Long Covid-19: drug trial results to watch in 2022
At least four long Covid-19 drug trial readouts are expected in 2022 that could shape the future of the therapeutic…
By
Pipeline Moves: Pfizer completes Phase I trial, boosts NASH program
iOnctura’s and Blade’s respective assets in idiopathic pulmonary fibrosis are also reviewed by Clinical Trials Arena.
By
Revealed: pharma leaders in precision, personalised medicine
GlobalData’s Thematic Research ecosystem ranks companies on a scale of 1 to 5 based on their likelihood to tackle issues…
By
Trial Activity Snapshot: Did Australia’s “zero-Covid” plan protect clinical trial activity?
In an exclusive, Clinical Trials Arena dives into Australia’s trial activity data to find out how the pandemic impacted the…
By
Biosimilars: top 10 pharma companies leading the way
The analysis is influenced by new biosimilars jobs, deals, patents, and mentions in company reports since January 2021.
By
Pipeline Moves: J&J ends ulcerative colitis trial, further study chances drop
Clinical Trials Arena reviews a total of six trials, including ones in gram-negative bacterial infections, hepatitis B, and obesity.
By
Moderna eyes combined Covid-19, flu booster by 2023
Moderna CEO Stéphane Bancel also said an Omicron-specific Covid-19 vaccine will enter clinical development in a matter of weeks.
By